AngioDynamics (ANGO) Misses Q3 EPS by 4c, Lowers FY15 Guidance

AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.12, $0.04 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $86.6 million versus the consensus estimate of $89.8 million.

AngioDynamics sees FY2015 EPS of $0.57-$0.60, may not compare to the consensus of $0.68. AngioDynamics sees FY2015 revenue of $356-360 million, versus prior guidance of $362-368 million and the consensus of $366.62 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike updates Q4 fiscal 2026 outlook with tariff refund benefit
• BofA lists top 5 themes driving next $1tn in incremental semi sales